SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards as investors react to increased spending forecasts related to AI, drawing comparisons to the company's metaverse investments; the community is debating whether this dip represents a buying opportunity or signals deeper concerns about Meta's direction, with some citing a one-time tax charge as the primary driver, while others point to overall market weakness or algorithmic reactions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the iconic Rage Guy meme, emphasizing a return to OG meme culture and community-driven growth. Discussions highlight the importance of belief and shared effort, with community members expressing bullish sentiment and encouraging each other to "RAGE ON" and "work for their bags". The movement is positioned as a cultural correction against soulless memecoins.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors anticipate the company's earnings report and how effectively it's monetizing data through AI partnerships. Community members are discussing revenue estimates, daily active user growth, and the potential for a post-earnings rally or selloff. Some are also pointing to potential connections with other trending stocks and broader market factors.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV); discussions center on whether the deal undervalues CORZ, especially given the potential for AI infrastructure growth. Some shareholders believe CORZ is worth more as a standalone company, citing peers and potential for new contracts, while others worry about financial stability without the merger. The vote outcome is uncertain, leading to speculation about future directions and potential board changes.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards as the community discusses concerns around declining traffic, margin pressures, and lowered sales outlook, potentially driven by consumer spending habits and pricing. Some traders believe the stock is oversold, presenting a buying opportunity, while others express concerns about the company's current leadership and competitive landscape. Community members are also debating if a change in strategy is needed to better appeal to a broader customer base.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed rumors of a potential buyout, sparking active discussions within the investment community. The speculation surfaces as the company focuses on oncology and prepares to report earnings in November. Community members are weighing the potential deal price and strategic implications for Moderna's future.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to renewed optimism fueled by raised FY25 EBITDA guidance and a potential short squeeze, with the community actively discussing target prices and the possibility of further upside. A top-line Q3 beat and recent earnings surprise are adding to the positive sentiment. Some traders are closely monitoring the stock's short interest and anticipating a significant price movement.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is seeing active discussion around its correlation to Bitcoin and upcoming earnings, with community members debating its valuation relative to its Bitcoin holdings and expressing concerns about potential downside. Some traders are closely watching options activity and speculating on potential catalysts, while others question the company's strategy and management. The stock's performance relative to Bitcoin's price movement remains a key talking point.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC is trending as investors digest recent earnings and a reduced dividend, leading to a sharp price decline. The community is debating whether this presents a value opportunity or signals deeper challenges for the company, with some citing an overreaction and oversold conditions. Bullish sentiment is building around potential for a price rebound given its inclusion in the S&P 500.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Bitcoin (BTC) dropped below $114,000 in&nbsp;pre-market U.S. hours on Wednesday, while Ripple’s native token (XRP), Solana (SOL), Cardano (ADA), and Dogecoin (DOGE) led the slide among&nbsp;other major tokens.The overall cryptocurrency market slipped around 1.3% over the past day, with the overall&nbsp;market capitalization slipping below $3.8 trillion.&nbsp;<a href="http://stocktwits.com/symbol/BTC.X">Bitcoin’s price</a> fell 0.7% in the last 24 hours, while retail sentiment on Stocktwits moved lower in&nbsp;the ‘bearish’ territory. Bitcoin’s current price is 7.2% below its all-time high of over $122,000, seen last month.&nbsp;<a href="http://stocktwits.com/symbol/XRP.X">XRP’s price</a> was down 4.4% and&nbsp;<a href="http://stocktwits.com/symbol/ADA.x">Cardano’s price</a> slipped around 3.9% in pre-market U.S. hours.<a href="https://stocktwits.com/symbol/ETH.X">Ethereum price</a> fell 1.7% in the last 24 hours, still above $3,600. On Stocktwits, retail sentiment around Ethereum remained in ‘bearish’ territory over the past day.&nbsp;<a href="https://stocktwits.com/symbol/SOL.X">Solana’s price</a> fell 4.2% and&nbsp;<a href="https://stocktwits.com/symbol/DOGE.X">Dogecoin’s price</a> dipped 3.6% over the past day.&nbsp;Weakness in the cryptocurrency market&nbsp;persisted as investors continued to withdraw money from U.S.-listed spot Bitcoin exchange-traded funds (ETFs). According to&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://sosovalue.com/assets/etf/us-btc-spot">data</a> from SoSoValue, the daily total net outflow amounted to $196.18 million on Tuesday, with Fidelity’s FBTC (FBTC) and BlackRock’s IBIT (IBIT) accounting for the biggest shares.&nbsp;This is the fourth day of outflows from U.S.-listed spot BTC ETFs, the longest streak since April. More than $114 million was withdrawn on Thursday, followed by $812 million on Friday and $333 million on Monday.Amid a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://blog.coinshares.com/volume-245-digital-asset-fund-flows-weekly-report-e4ac31e2961a">choppy week</a> of ETF flows, $298 million worth of crypto was liquidated over the past day, according to Coinglass&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.coinglass.com/LiquidationData">data</a>. Long liquidations were around $210 million, while short liquidations totaled $87 million. Ethereum experienced the largest liquidations of $89 million, followed by Bitcoin at $43 million.Crypto-linked stocks were in the doldrums during pre-market trade on Wednesday. Shares of Strategy (MSTR), the largest corporate holder of Bitcoin, edged 0.7% higher. Bitcoin miner Riot Platforms (RIOT) stock edged 0.09% higher, and shares of its peer, Mara Holdings (MARA), gained 0.06%. Crypto exchange Coinbase Global’s (COIN) shares were up 1.2% in pre-market trade.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ray-dalio-warns-of-fiat-trust-breakdown-says-gold-standard-return-is-possible/chrLMkxRd20">Ray Dalio Warns Of Fiat Trust Breakdown, Says Gold Standard Return Is Possible</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A neon sign advertises a Bitcoin and Ethereum crypto currency exchange in Warsaw, Poland, on January 4, 2025.

Bitcoin Drops Below $114K With XRP, Solana, Dogecoin Leading The Slide – ETF Outflows Hit $1.3B Over the Last 4 Days

Weakness in the cryptocurrency market remained as investors continued to withdraw money from U.S.-listed spot Bitcoin exchange-traded funds.

Cryptocurrency

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Nasdaq-listed American Depository Receipts (ADRs) of Genmab A/S (GMAB) rose over 1% on Thursday morning after Johnson &amp; Johnson (JNJ)<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/04/15/3061529/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-First-Quarter-of-2025.html"> announced</a> that sales of the oncology drug Darzalex rose over 20% in the first quarter of 2025.Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&amp;J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab.Genmab licensed daratumumab to Johnson &amp; Johnson unit Janssen Biotech, Inc. in August 2012.Darzalex is a prescription medication used to treat multiple myeloma, a type of blood cancer. For the three months through the end of March, Johnson &amp; Johnson reported sales of $3.24 billion for Darzalex, marking a growth of 20.3% year-on-year.Darzalex accounted for over 23% of the company’s overall sales in its innovative medicine segment and nearly 15% of its overall reported sales.Darzalex sales in the U.S. jumped 25% to $1.83 billion during the quarter, while sales outside the country jumped 15% to $1.41 billion.The rise in Darzalex sales enabled the company to offset the 34% drop in sales of its immunology drug Stelara to $1.63 billion.On Stocktwits, retail sentiment around Genmab fell marginally while staying within ‘extremely bullish’ territory over the past 24 hours, while message volume dropped to ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:645/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_9_35_32_AM_png_f443284110.webp" alt="GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits" width="645" height="149"><figcaption>GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that Genmab shares are cheap.<a href="https://stocktwits.com/Pika_Capital/message/611668890">https://stocktwits.com/Pika_Capital/message/611668890</a><a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> fell by about 7% year-to-date and over 33% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dow-jones-futures-tick-higher-as-investors-await-earnings-monitor-tariff-developments/chQRaHyRbau">Dow Jones Futures Tick Higher As Investors Await Earnings, Monitor Tariff Developments</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab. 

Equity

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a settlement payment with the National Institutes of Health, drawing a cautious response from retail investors.The payment reportedly comprises $750 million as a settlement for claimed royalties during calendar years 2020-2023, and $41.5 million consideration for the NIH towards an amended and restated license agreement, dated December 20.BioNTech, a clinical-stage biotechnology company, focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases.BioNTech had been in discussions with the National Institutes of Health concerning royalties and other amounts allegedly owed on certain sales along with its collaboration partner Pfizer in connection to COVID-19 vaccine, the Fly.com reported.Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.<stembedurl>https://stocktwits.com/taxplanr/message/597983247</stembedurl> <stembedurl>https://stocktwits.com/taxplanr/message/597861544</stembedurl> &nbsp;The Fly.com report said the company's execution of the settlement agreement wasn’t an admission of liability as the company denied it had any legal liabilities or was in violation of any laws.NIH has reportedly agreed to consider any alleged noncompliance under the amended license agreement to be resolved for the period up to and including January 1, 2024, including any claimed historical royalty payments allegedly owed by the company prior to January 1, 2024.In parallel, BioNTech and the NIH also entered into the amended license agreement that provides a “framework” for a license for use in combination products including the COVID-19 vaccine used in combination with other active pharmaceutical ingredients.The settlement agreement requires Pfizer to reimburse BioNTech for $364.5 million of the claimed royalties paid to the NIH for 2020-2023 sales, the report added.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image. Source: Getty Images

BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious

Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.

BeiGene (<a class="mention" data-mention="$BGNE" data-symbol-id="BGNE" href="https://stocktwits.com/symbol/BGNE" target="_blank">$BGNE</a>) shares jumped over 5% pre-market Wednesday, with the oncology company’s stock poised to reach a two-week high after the European Commission approved its drug Tevimbra (Tislelizumab) for first-line treatment of gastric and esophageal cancers.The approval allows Tevimbra, in combination with chemotherapy, to treat esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction adenocarcinoma.&nbsp;Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone, demonstrating statistically significant and clinically meaningful benefits.Mark Lanasa, Chief Medical Officer for Solid Tumors at BeiGene, emphasized Tevimbra’s role as the cornerstone of the company’s solid tumor portfolio, noting that more than 1.3 million patients worldwide have been treated with the drug.&nbsp;The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.Esophageal cancer, which accounts for over 90% of esophageal squamous cell carcinoma cases, is one of the deadliest cancers. Beigene says it is projected to increase by nearly 60% to 957,000 annual cases by 2040, highlighting the urgent need for better treatment options.BeiGene has been expanding rapidly, recently reporting $1 billion in quarterly revenue, driven by U.S. and European product sales, and opening an $800 million R&amp;D and manufacturing facility in New Jersey.&nbsp;The company had also announced plans to rebrand as “BeOne Medicines Ltd.” and change its ticker to “ONC” following shareholder approval, signaling its commitment to global oncology leadership.<figure class="image"><a href="https://stocktwits.com/symbol/BGNE"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BGNE_sentiment_and_message_volume_Nov_27_premarket_749418ab8f.png" alt="BGNE sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>BGNE sentiment and message volume Nov 27 premarket as of 7:30 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment shifted from ‘neutral’ to ‘extremely bullish’ early on Wednesday following the approval news, accompanied by a surge in message volume.&nbsp;TD Cowen recently reiterated a ‘Buy’ rating on BeiGene and raised its price target to $260, citing the company’s robust pipeline, which it described as among the best in biotech.BeiGene stock has gained more than 8% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-slides-after-fuzzy-panda-short-call/cJIWDFNRWc">ASP Isotopes Stock Fizzles After Fuzzy Panda Short Call: Retail Eyes Opportunity</a>

Clinical trial data showed that Tevimbra improved median overall survival to 17.2 months versus 10.6 months with chemotherapy alone.

BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

FBT
First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FBT News

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund